IN8BIO INC (INAB) Stock Price, Forecast & Analysis
NASDAQ:INAB • US45674E2081
INAB Key Statistics, Chart & Performance
The current stock price of INAB is 1.71 USD. In the past month the price decreased by -12.76%. In the past year, price decreased by -78.82%.
INAB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to INAB. When comparing the yearly performance of all stocks, INAB is a bad performer in the overall market: 94.02% of all stocks are doing better.
INAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INAB. INAB has a bad profitability rating. Also its financial health evaluation is rather negative.
INAB Financial Highlights
Over the last trailing twelve months INAB reported a non-GAAP Earnings per Share(EPS) of -5.39. The EPS increased by 76.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -123.2% | ||
| ROE | -156.63% | ||
| Debt/Equity | 0 |
INAB Forecast & Estimates
10 analysts have analysed INAB and the average price target is 50.24 USD. This implies a price increase of 2837.72% is expected in the next year compared to the current price of 1.71.
INAB Ownership
INAB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.47 | 397.113B | ||
| AMGN | AMGEN INC | 16.83 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.12 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.55 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.45 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.36 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.09 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INAB
Company Profile
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Company Info
IN8BIO INC
Empire State Building, 350 5Th Avenue, Suite 5330
New York City NEW YORK US
CEO: William Ho
Employees: 18
Phone: 13026587581
IN8BIO INC / INAB FAQ
What does IN8BIO INC do?
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Can you provide the latest stock price for IN8BIO INC?
The current stock price of INAB is 1.71 USD. The price increased by 3.01% in the last trading session.
Does INAB stock pay dividends?
INAB does not pay a dividend.
What is the ChartMill rating of IN8BIO INC stock?
INAB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is IN8BIO INC (INAB) stock traded?
INAB stock is listed on the Nasdaq exchange.
Who owns IN8BIO INC?
You can find the ownership structure of IN8BIO INC (INAB) on the Ownership tab.